Clinical Trial Application for Cat Hair Allergen Treatment Receives Regulatory Acceptance

Stock News06-18

Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd. (300357.SZ) has announced that it has received a formal notice of acceptance from the National Medical Products Administration for its clinical trial application of a cat hair allergen treatment.

The product is designed to work in conjunction with the company's already marketed "Cat Dander Allergen Skin Prick Test Solution" (National Drug Approval Number S20240056), with the potential to provide a comprehensive "diagnosis plus treatment" solution for patients suffering from cat dander allergies.

Furthermore, this new treatment complements the company's existing line of desensitization products, which includes "Dust Mite Drops" (National Drug Approval Number S20060012) and "Artemisia Pollen Allergen Sublingual Drops" (National Drug Approval Number S20210001).

The company aims to offer desensitization treatments for a wider range of allergens to benefit more patients with allergic diseases. This development is also expected to further enrich the company's desensitization therapy product pipeline, helping to secure its ongoing competitive advantage in this field.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179057936?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 17:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179057936","market":"us","top_or_hot":-1,"title":"Clinical Trial Application for Cat Hair Allergen Treatment Receives Regulatory Acceptance","media":"Stock News","content":"<p>Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd. (<b>300357.SZ</b>) has announced that it has received a formal notice of acceptance from the National Medical Products Administration for its clinical trial application of a cat hair allergen treatment.<br><br>The product is designed to work in conjunction with the company's already marketed \"Cat Dander Allergen Skin Prick Test Solution\" (National Drug Approval Number S20240056), with the potential to provide a comprehensive \"diagnosis plus treatment\" solution for patients suffering from cat dander allergies.<br><br>Furthermore, this new treatment complements the company's existing line of desensitization products, which includes \"Dust Mite Drops\" (National Drug Approval Number S20060012) and \"Artemisia Pollen Allergen Sublingual Drops\" (National Drug Approval Number S20210001).<br><br>The company aims to offer desensitization treatments for a wider range of allergens to benefit more patients with allergic diseases. This development is also expected to further enrich the company's desensitization therapy product pipeline, helping to secure its ongoing competitive advantage in this field.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clinical Trial Application for Cat Hair Allergen Treatment Receives Regulatory Acceptance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClinical Trial Application for Cat Hair Allergen Treatment Receives Regulatory Acceptance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-18 17:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd. (<b>300357.SZ</b>) has announced that it has received a formal notice of acceptance from the National Medical Products Administration for its clinical trial application of a cat hair allergen treatment.<br><br>The product is designed to work in conjunction with the company's already marketed \"Cat Dander Allergen Skin Prick Test Solution\" (National Drug Approval Number S20240056), with the potential to provide a comprehensive \"diagnosis plus treatment\" solution for patients suffering from cat dander allergies.<br><br>Furthermore, this new treatment complements the company's existing line of desensitization products, which includes \"Dust Mite Drops\" (National Drug Approval Number S20060012) and \"Artemisia Pollen Allergen Sublingual Drops\" (National Drug Approval Number S20210001).<br><br>The company aims to offer desensitization treatments for a wider range of allergens to benefit more patients with allergic diseases. This development is also expected to further enrich the company's desensitization therapy product pipeline, helping to secure its ongoing competitive advantage in this field.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300357","symbol_name":"我武生物","start_time":0,"source_url":"","article_id":"1179057936","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179057936","pubTimestamp":1781773954,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd. (300357.SZ) has announced that it has received a formal notice of acceptance from the National Medical Products Administration for its clinical trial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300357":"我武生物","BK0239":"医药制造","BK0028":"国家队"},"translate_title":"猫毛过敏原治疗临床试验申请获监管机构受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300357":1},"content_text":"Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd. (300357.SZ) has announced that it has received a formal notice of acceptance from the National Medical Products Administration for its clinical trial application of a cat hair allergen treatment.The product is designed to work in conjunction with the company's already marketed \"Cat Dander Allergen Skin Prick Test Solution\" (National Drug Approval Number S20240056), with the potential to provide a comprehensive \"diagnosis plus treatment\" solution for patients suffering from cat dander allergies.Furthermore, this new treatment complements the company's existing line of desensitization products, which includes \"Dust Mite Drops\" (National Drug Approval Number S20060012) and \"Artemisia Pollen Allergen Sublingual Drops\" (National Drug Approval Number S20210001).The company aims to offer desensitization treatments for a wider range of allergens to benefit more patients with allergic diseases. This development is also expected to further enrich the company's desensitization therapy product pipeline, helping to secure its ongoing competitive advantage in this field.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179057936","isCrawlerRequest":true}